Arrow Clinical Trials — research payments reported

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$923,072	44
2024	Research	$550,882	14

Breakdown

Who paid Research payments · program years 2024–2025

E.R. Squibb & Sons, L.L.C. $989,217 12 payments
Alnylam Pharmaceuticals Inc. $169,763 26 payments
Novartis Pharmaceuticals Corporation $123,812 3 payments
AstraZeneca UK Limited $78,657 1 payment
Celgene Corporation $53,600 1 payment
ACADIA Pharmaceuticals Inc $42,298 11 payments
ITI, Inc. $16,608 4 payments

Studies the money was for Research payments · program years 2024–2025

A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) $466,189 2 payments
Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer s Disease (TargetT $308,287 1 payment
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) $169,763 26 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease $111,958 2 payments
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease $96,322 2 payments
a phase one,randomized,double blind,placeb controlled,multi centre study to assess the pharmacodynamics,safety,and tolerability of azd4144 in participants with established atherosclerotic cardiovascular and chronic kidney disease $78,657 1 payment
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib $74,287 2 payments
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) $49,525 1 payment
Acp-204-006 $42,298 11 payments
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia $31,151 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.